effective combined therapy of meglumine antimoniate and co-trimoxazole for cutaneous leishmaniasis: a study in Quetta City

Objective: To evaluate the efficacy of combined therapy of meglumine antimoniate and co-trimoxazole in cutaneous leishmaniasis [CL]

Methods: 180 patients with active lesions of CL, confirmed by fine needle aspiration cytology [FNAC] were treated with combined therapy of meglumine antimoniate [Glucantime] and co-trimoxazole [Septran] for 20 days

Results: Out of 180 patients, 160 [88.9%] were cured. A few patients reported nausea, vomiting, glossitis, skin rashes and folate deficiency

Conclusion: The combined therapy of meglumine antimoniate [Glucantime] and co-trimoxazole [Septran] is more effective than the previously reported combined therapies